GSK vs. RXRX
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Recursion Pharmaceuticals, Inc. (RXRX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or RXRX.
Performance
GSK vs. RXRX - Performance Comparison
Returns By Period
In the year-to-date period, GSK achieves a -6.46% return, which is significantly higher than RXRX's -37.37% return.
GSK
-6.46%
-12.50%
-24.30%
-1.51%
-1.61%
1.53%
RXRX
-37.37%
-11.91%
-34.45%
-7.42%
N/A
N/A
Fundamentals
| GSK | RXRX | |
|---|---|---|
| Market Cap | $73.63B | $2.17B |
| EPS | $1.56 | -$1.54 |
| Total Revenue (TTM) | $31.27B | $65.18M |
| Gross Profit (TTM) | $22.46B | $1.96M |
| EBITDA (TTM) | $6.33B | -$373.35M |
Key characteristics
| GSK | RXRX | |
|---|---|---|
| Sharpe Ratio | 0.07 | -0.17 |
| Sortino Ratio | 0.25 | 0.34 |
| Omega Ratio | 1.03 | 1.04 |
| Calmar Ratio | 0.06 | -0.16 |
| Martin Ratio | 0.17 | -0.33 |
| Ulcer Index | 9.29% | 42.44% |
| Daily Std Dev | 21.65% | 82.66% |
| Max Drawdown | -55.21% | -88.97% |
| Current Drawdown | -25.62% | -85.06% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between GSK and RXRX is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
GSK vs. RXRX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK vs. RXRX - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.67%, while RXRX has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.67% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% | 4.43% |
RXRX Recursion Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
GSK vs. RXRX - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.21%, smaller than the maximum RXRX drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for GSK and RXRX. For additional features, visit the drawdowns tool.
Volatility
GSK vs. RXRX - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK) is 6.01%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 21.74%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GSK vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities